Dermapharm Holding SE, the Grünwald-based branded pharmaceuticals manufacturer listed on the SDAX, has published its results for the first nine months of 2026, reporting consolidated revenue of EUR 884.4 million, up 1.7% year on year. The group's "Branded pharmaceuticals" segment was the primary growth driver, with revenue rising 8.1% to EUR 486.2 million, supported by organic growth and contributions from the newly acquired Mucos and F. Trenka businesses. The Board of Management has confirmed its full-year 2026 guidance, projecting consolidated revenue of EUR 1,182–1,218 million and adjusted EBITDA of EUR 331–341 million, a signal investors may view as a measure of management confidence.

Key Points

  • Dermapharm Holding SE (0A5J), SDAX-listed branded pharmaceuticals manufacturer based in Grünwald, Germany
  • Nine-month 2026 consolidated revenue rose 1.7% to EUR 884.4 million; adjusted EBITDA up 5.1% to EUR 248.1 million
  • Branded pharmaceuticals segment revenue grew 8.1% to EUR 486.2 million; full-year 2026 guidance confirmed at EUR 1,182–1,218 million revenue and EUR 331–341 million adjusted EBITDA
  • Investors may be watching whether the parallel import business stabilises following planned portfolio optimisation measures

Branded Pharmaceuticals Segment Delivers 8.1% Revenue Growth, Boosted by Mucos and F. Trenka Acquisitions

The "Branded pharmaceuticals" segment remained the group's core growth engine in the nine months to September 2026, with revenue climbing 8.1% to EUR 486.2 million from EUR 449.8 million in the prior-year period. The announcement states that this performance was driven by strong organic growth in both the domestic German business and the international business, alongside incremental revenue from the recently completed acquisitions of Mucos and F. Trenka. Adjusted EBITDA for the segment rose 6.7% to EUR 213.0 million, though the adjusted EBITDA margin edged slightly lower to 43.8% from 44.4%, reflecting the integration costs associated with the new acquisitions.

Group Adjusted EBITDA Margin Expands to 28.0% as Profitability Outpaces Revenue Growth

At the consolidated level, adjusted EBITDA increased by 5.1% to EUR 248.1 million, outpacing the 1.7% revenue rise and lifting the adjusted EBITDA margin by 0.9 percentage points to 28.0%. Unadjusted EBITDA was EUR 266.9 million, equating to a margin of 30.2%. The nine-month 2026 EBITDA was adjusted for non-recurring items amounting to EUR -18.8 million, primarily linked to provisional negative goodwill in connection with the Mucos acquisition. The "Other healthcare products" segment, which includes Arkopharma and Euromed, reported stable adjusted EBITDA margins of 15.7% despite a modest 2.6% revenue decline to EUR 261.9 million.

Parallel Import Business Segment Continues Planned Revenue Decline Under axicorp Portfolio Optimisation

Dermapharm's parallel import business, operated under the axicorp brand and currently the seventh largest parallel importer in Germany by revenue, saw revenue fall 9.5% to EUR 136.3 million, a decline the company attributes to deliberate portfolio optimisation measures introduced in the prior year. Adjusted EBITDA for the segment remained negative at EUR -2.0 million. The announcement notes that lower personnel and other operating expenses could not fully offset the gross profit margin reduction, underscoring this segment as a continuing drag on group-level performance that investors may continue to monitor.

Board Confirms 2026 Full-Year Guidance of Up to EUR 1,218 Million Revenue and EUR 341 Million Adjusted EBITDA

Based on nine-month performance and expectations for the fourth quarter, Dermapharm's Board of Management has confirmed its previously published outlook for full-year 2026. The group targets consolidated revenue in the range of EUR 1,182–1,218 million and adjusted EBITDA of EUR 331–341 million. Dermapharm, which holds more than 1,400 marketing authorisations across more than 400 active pharmaceutical ingredients, operates production, development and distribution locations across Germany, the broader European market, and the United States, providing a geographically diversified base from which to pursue both organic and acquisition-led growth.